Oxford BioMedica PLC

142 articles with Oxford BioMedica PLC

• Oxford BioMedica PLC and Sanofi-Aventis (France) Enter New Collaboration Worth $50 Million

  4/30/2009

• Oxford BioMedica PLC: Preliminary Results For The Year Ended 31 December 2008

  3/12/2009

• Oxford BioMedica PLC FY Revenue Up to 18.4 Million Stage

  3/12/2009

• Oxford BioMedica PLC Receives Further Investment Under Agreement Led by the Foundation Fighting Blindness

  2/5/2009

• Bavarian Nordic's Case Against Oxford BioMedica PLC

  1/12/2009

• Oxford BioMedica PLC Announces Six-Month Efficacy Results With Low Dose of ProSavin(R) in Phase I/II Trial in Parkinson’s Disease

  11/19/2008

• Oxford BioMedica PLC Announces Two Scientific Presentations of ProSavin in Parkinson's Disease

  11/14/2008

• Cancer Drug May Increase Patient Survival, Oxford BioMedica PLC Says

  10/24/2008

• Oxford BioMedica PLC Announces Appointment of John Dawson as Chief Executive Officer

  10/14/2008

• Oxford BioMedica PLC Announces Promising Interim Phase 1/2 Results

  9/9/2008

• GeneThera, Inc. Rules Out Oxford BioMedica PLC Offer

  9/3/2008

• Oxford BioMedica PLC H1 Net Loss Narrows, CEO Leaves

  8/29/2008

• Oxford BioMedica PLC Leaps After Rejecting GeneThera, Inc. Bid

  8/15/2008

• Sanofi-Aventis (France), Oxford BioMedica PLC Say Cancer Drug Won't Meet Study Goal

  7/11/2008

• UK Biotech Wargame Gains Support from Leading Companies in the Industry

  7/8/2008

• Bavarian Nordic Files Patent Infringement Suit Against Oxford BioMedica PLC

  6/30/2008

• Oxford BioMedica PLC Reports Encouraging New Phase 2 Trial Results

  3/25/2008

• Sigma-Aldrich Corporation, Oxford BioMedica PLC and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents

  3/10/2008

• Oxford BioMedica PLC Completes Patient Recruitment for Phase 3 Study

  3/10/2008

• Oxford BioMedica PLC Announces Appointment of Non-executive Director

  3/10/2008